NASDAQ:PRTA - Prothena Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.53 -0.12 (-1.24 %) (As of 05/19/2019 04:45 AM ET)Previous Close$9.53Today's Range$9.46 - $9.7552-Week Range$8.63 - $15.91Volume260,929 shsAverage Volume253,472 shsMarket Capitalization$379.96 millionP/E RatioN/ADividend YieldN/ABeta2.4 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland. Receive PRTA News and Ratings via Email Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTA Previous Symbol CUSIPN/A CIK1559053 Webwww.prothena.com Phone011-353-1236-2500Debt Debt-to-Equity Ratio0.07 Current Ratio27.85 Quick Ratio27.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$950,000.00 Price / Sales399.96 Cash FlowN/A Price / Cash FlowN/A Book Value$7.83 per share Price / Book1.22Profitability EPS (Most Recent Fiscal Year)($3.61) Net Income$-155,650,000.00 Net Margins-13,978.88% Return on Equity-33.45% Return on Assets-21.75%Miscellaneous Employees59 Outstanding Shares39,870,000Market Cap$379.96 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Prothena (NASDAQ:PRTA) Frequently Asked Questions What is Prothena's stock symbol? Prothena trades on the NASDAQ under the ticker symbol "PRTA." How were Prothena's earnings last quarter? Prothena Co. PLC (NASDAQ:PRTA) announced its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.60) by $0.08. The biotechnology company earned $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. Prothena had a negative net margin of 13,978.88% and a negative return on equity of 33.45%. View Prothena's Earnings History. When is Prothena's next earnings date? Prothena is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Prothena. What price target have analysts set for PRTA? 3 brokers have issued 12-month price objectives for Prothena's shares. Their predictions range from $12.00 to $13.77. On average, they expect Prothena's share price to reach $12.8850 in the next year. This suggests a possible upside of 35.2% from the stock's current price. View Analyst Price Targets for Prothena. What is the consensus analysts' recommendation for Prothena? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prothena. What are Wall Street analysts saying about Prothena stock? Here are some recent quotes from research analysts about Prothena stock: 1. According to Zacks Investment Research, "Prothena reported narrower-than-expected loss in the first quarter of 2019. The company's license agreement with Roche for prasinezumab not only boosts pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. The company also entered an agreement with Celgene to develop its pipeline using the latter’s expertise. The company earlier had discontinued the development of its lead pipeline candidate, NEOD001. Prothena has very limited number of candidates in its pipeline. Now, investors are likely to focus on the ongoing phase II study of prasinezumab, though results from this mid-stage study are not expected before 2020. However, the lack of promising candidates is a concern. Shares have underperformed the industry in the past twelve months." (5/15/2019) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month PT of $18. With discontinuation of NEOD001 development announced in April (our report here), investors are likely to focus on PRX002/RG7935 development as a treatment for Parkinson’s disease (PD). The company has guided to expectation for data from the Phase 2 PASADENA trial in 2020. Release of pharmacodynamic data from lower-dose cohorts of ATTR amyloidosis treatment PRX004 are anticipated in 2019." (8/8/2018) Has Prothena been receiving favorable news coverage? News headlines about PRTA stock have been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Prothena earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. Who are some of Prothena's key competitors? Some companies that are related to Prothena include Innoviva (INVA), Endo International (ENDP), Cambrex (CBM), Heron Therapeutics (HRTX), Gossamer Bio (GOSS), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Mallinckrodt (MNK), Opko Health (OPK), Corcept Therapeutics (CORT), Apellis Pharmaceuticals (APLS), Phibro Animal Health (PAHC), Theravance Biopharma (TBPH), Epizyme (EPZM) and Inflarx (IFRX). What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), Celgene (CELG), Synergy Pharmaceuticals (SGYP), Perrigo (PRGO) and BIOLINERX LTD/S (BLRX). Who are Prothena's key executives? Prothena's management team includes the folowing people: Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)Mr. Tran B. Nguyen, CFO & COO (Age 45)Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)Dr. Wagner M. Zago, Chief Scientific Officer (Age 46) Who are Prothena's major shareholders? Prothena's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (10.50%), BlackRock Inc. (8.36%), Dimensional Fund Advisors LP (4.22%), Wellington Management Group LLP (3.00%), Morgan Stanley (1.71%) and Geode Capital Management LLC (1.37%). Company insiders that own Prothena stock include Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker and Tara Nickerson. View Institutional Ownership Trends for Prothena. Which institutional investors are selling Prothena stock? PRTA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, FMR LLC, BlackRock Inc., California State Teachers Retirement System, Charles Schwab Investment Management Inc., Zurcher Kantonalbank Zurich Cantonalbank and Northern Trust Corp. View Insider Buying and Selling for Prothena. Which institutional investors are buying Prothena stock? PRTA stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Dimensional Fund Advisors LP, Tang Capital Management LLC, JPMorgan Chase & Co., Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, Geode Capital Management LLC and Acadian Asset Management LLC. View Insider Buying and Selling for Prothena. How do I buy shares of Prothena? Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Prothena's stock price today? One share of PRTA stock can currently be purchased for approximately $9.53. How big of a company is Prothena? Prothena has a market capitalization of $379.96 million and generates $950,000.00 in revenue each year. The biotechnology company earns $-155,650,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Prothena employs 59 workers across the globe. What is Prothena's official website? The official website for Prothena is http://www.prothena.com. How can I contact Prothena? Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected] MarketBeat Community Rating for Prothena (NASDAQ PRTA)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 430 (Vote Outperform)Underperform Votes: 291 (Vote Underperform)Total Votes: 721MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Put Option Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.